Coya Therapeutics, INC 8-K filings

Coya Therapeutics reported Q2 2026 results, noting progress in its ALSTARS Phase 2 ALS trial, FDA Fast Track designation for COYA 302, and plans for a new FTD study, while managing a net loss of $6.6 million.

Coya Therapeutics stockholders re-elected two Class I directors and ratified the appointment of their independent auditor.

Coya Therapeutics has entered into a Sales Agreement with Leerink Partners to offer and sell up to $30 million of its common stock.

Coya Therapeutics reports Q1 2026 financial results, highlights FDA Fast Track Designation for COYA 302 for ALS, and provides corporate and pipeline updates.

Coya Therapeutics founder Dr. Howard Berman steps down as Executive Chairman, with industry veteran Mark H. Pavao appointed as an independent director.

Coya Therapeutics announced its fiscal year 2025 financial results and provided a corporate update highlighting significant progress in its clinical programs and strengthened financial position.

Coya Therapeutics announced an $11.1 million private placement led by Dr. Reddys Laboratories and Greenlight Capital to fund commercial readiness for COYA 302.

Coya Therapeutics, Inc. announced an unaudited cash balance of $46.8 million as of December 31, 2025, projecting a cash runway into the second half of 2027, with topline data from its ALSTARS Phase 2 trial expected in the first quarter of 2027.

Coya Therapeutics announced positive results from a proof-of-concept study for its low-dose IL-2 and CTLA4-Ig combination treatment in Frontotemporal Dementia patients.

Coya Therapeutics announced the receipt of a $4.2 million milestone payment from Dr. Reddy's Laboratories, triggered by the first patient dosing in its ALSTARS trial for amyotrophic lateral sclerosis (ALS).

Coya Therapeutics announced its third quarter 2025 financial results, highlighting progress in its neurodegenerative disorder pipeline and an extended cash runway.

Coya Therapeutics, a clinical-stage biotechnology company, announced the pricing of an upsized public offering of common stock, expecting to raise approximately $23.0 million in gross proceeds.

Coya Therapeutics received a $4.2 million milestone payment from Dr. Reddy's Laboratories following FDA acceptance of its IND for COYA 302 in ALS.

Coya Therapeutics announced its second quarter 2025 financial results, reporting an increased net loss and decreased collaboration revenue, while highlighting upcoming key clinical milestones including an FDA decision for COYA 302 in ALS.

Coya Therapeutics announced a delay in the U.S. Food and Drug Administration's review of its Investigational New Drug Application for COYA 302, pushing back the decision date for its Phase 2 ALS study.

Coya Therapeutics, Inc. has resubmitted its Investigational New Drug Application for COYA 302 to the FDA, including previously requested non-clinical data, moving closer to initiating its Phase 2 study for Amyotrophic Lateral Sclerosis.

Coya Therapeutics, Inc. announced the successful election of three Class III directors and the ratification of Weaver and Tidwell, L.L.P. as its independent registered public accounting firm at its Annual Meeting of Stockholders held on June 26, 2025.

Coya Therapeutics announces its Q1 2025 financial results, highlighting progress in clinical trials and pipeline expansion.

Coya Therapeutics announces its FY2024 financial results, highlighting progress in clinical trials and pipeline expansion, with a focus on neurodegenerative diseases.

Coya Therapeutics reported positive results from an Alzheimer's disease study, provided a corporate update, and announced its third quarter 2024 financial results.

Dr. Hideki Garren has resigned from Coya Therapeutics' Board of Directors, effective immediately, due to a conflict of interest with his new employer.

Coya Therapeutics has appointed Dr. Arun Swaminathan as the new CEO, effective November 1, 2024, while Dr. Howard Berman transitions to Executive Chairman.

Coya Therapeutics' Phase 2 trial of low-dose Interleukin-2 (LD IL-2) in Alzheimer's patients met its primary and secondary endpoints, showing safety and an increase in regulatory T cells.

Coya Therapeutics has entered into a securities purchase agreement for a $10 million private placement to fund general corporate purposes and support its drug development pipeline.

Coya Therapeutics has announced a planned management change, with Arun Swaminathan promoted to CEO effective November 1, 2024, succeeding Howard Berman who will transition to Executive Chairman.

Coya Therapeutics announced its second quarter 2024 financial results, highlighted by a $5 million strategic investment and progress in its clinical programs, while also noting a delay in a planned Phase 2 study.

Coya Therapeutics' Phase 2 trial for ALS treatment, COYA 302, is delayed due to an FDA request for additional non-clinical data.

Coya Therapeutics has amended its agreement with Dr. Reddy's Laboratories, receiving $3.85 million in funding for a Phase 2 clinical trial and a waiver of the first $6 million in royalty payments.

Coya Therapeutics has received a $5 million investment from the Alzheimers Drug Discovery Foundation to support the development of its COYA 302 therapy for Frontotemporal Dementia.

Coya Therapeutics announced its first quarter 2024 financial results, highlighted by an expanded clinical pipeline and progress in regulatory discussions.